Journal of Crohn's & colitis最新文献

{"title":"Day 3 Oxford Criteria Predict Steroid non-response for Acute Severe Ulcerative Colitis in the Post Biologic Era.","authors":"Sudheer K Vuyyuru, Lotus Alphonsus, Theshani Amalka De Silva, Virginia Solitano, Leonardo Guizzetti, Terry Ponich, Melanie Beaton, Jamie Gregor, Brian Yan, Michael Sey, Vipul Jairath","doi":"10.1093/ecco-jcc/jjaf131","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf131","url":null,"abstract":"<p><strong>Background and aims: </strong>Outcomes of patients admitted with acute severe ulcerative colitis(ASUC) in the post biologic era are under explored, as well as ability of scoring indices to predict early steroid non-response.</p><p><strong>Methods: </strong>This Retrospective cohort study included adults hospitalized with ASUC(2010-2022) at London Health Sciences Centre, Canada. Steroid response, need for rescue therapy, colectomy during index hospitalization and colectomy and hospitalization at 3- and 12-months following discharge was assessed. Logistic regression identified predictors of steroid non-response, defined as need for rescue therapy or colectomy during hospitalization.</p><p><strong>Results: </strong>Of 261 adults hospitalized with ASUC(male : 51.7%, mean age : 40.6 years), 71.2% had extensive colitis. After intravenous corticosteroid therapy during index admission, 55.7%(n = 147) had response, 37.9%(n = 99) received rescue therapy (infliximab: 98, tofacitinib: 1 and cyclosporine: 0), and 8%(21/261) underwent colectomy. Additionally, 11.6%(28/240) of patients discharged from hospital underwent colectomy within the first 12 months (8.3% at 3-months and 3.3% between 3-12 months). There was no difference between steroid responders and steroid non-responders for colectomy(11%vs12.6%) or hospitalization(33.5%vs32.6%) at 12 months. The overall cumulative probabilities of colectomy of entire cohort at 1 year, 3 years and 5 years were 13.5%, 16.1%, and 17.4%, respectively. On multivariate analysis, Day-3 Oxford criteria was the only factor found to be statistically significant in predicting steroid non-response(odds ratio 4.70, 95%CI [1.06-20.80]).</p><p><strong>Conclusions: </strong>Day-3 Oxford criteria was an independent predictor of steroid non-response. The risk of colectomy remains substantial after discharge despite low in-hospital colectomy rate following an episode of ASUC. Initial steroid response did not affect long-term colectomy rate at 12 months.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatiotemporal analysis of Crohn's disease reveals PECAM2 signaling at the basis of inflammation-to-fibrosis transition.","authors":"Luca Massimino, Tommaso Lorenzo Parigi, Matteo Riva, Sabrina Nicolò, Carmela Errico, Salvatore Spanò, Sara Mino, Mattia Bugatti, Alice Frontali, Federico Scarfò, Andrea Vignali, Andrea Municchi, Vincenzo Villanacci, Luca Albarello, Maurilio Ponzoni, Virginia Solitano, Alberto Malesci, Vipul Jairath, Laurent Peyrin-Biroulet, Pierpaolo Sileri, Silvio Danese, Federica Ungaro","doi":"10.1093/ecco-jcc/jjaf130","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf130","url":null,"abstract":"<p><strong>Background and aims: </strong>Crohn's disease is a chronic inflammatory disease of the bowel, often complicated by fibrotic strictures, for which medical treatment is lacking, and surgery is commonly required. The mechanisms underlying the progression from chronic inflammation to fibrosis are not yet defined. We aim to unravel Crohn's disease pathogenesis using a cutting-edge computational pipeline combining several available tools.</p><p><strong>Methods: </strong>Spatial transcriptomics was performed on 13 surgical specimens, including inflamed and fibrotic Crohn's disease tissues and healthy controls. The resulting spatial data were integrated with single-cell RNA sequencing to trace the cellular and molecular transitions from healthy intestine to fibrotic tissue. Ligand-receptor interaction and pseudotime analyses were employed to infer dynamic cell-cell communication networks and lineage trajectories. Key computational findings were validated through immunostaining in an independent cohort of Crohn's disease patients. Finally, the therapeutic relevance of the identified target was evaluated in a TNBS-induced chronic colitis mouse model upon CD38 inhibitor administration.</p><p><strong>Results: </strong>We demonstrated that intestinal cytoarchitecture was rearranged while chronic inflammation progressed. Crohn's disease-associated fibrosis evolved within the mesenchymal compartment, driven by PECAM2 signaling through PECAM1-CD38 interaction. In parallel, ApoA signaling, particularly APOA1-ABCA interaction, emerged as relevant for maintaining epithelial and stromal homeostasis, while its downregulation was associated with fibrosis development. Moreover, CD38 signaling inhibition effectively reduced colitis symptoms and colon thickening in the experimental TNBS-induced model of chronic inflammation.</p><p><strong>Conclusions: </strong>Our results provide insights into CD38-driven fibrosis and indicate that PECAM2 signaling blockade could reduce the development of strictures in patients with Crohn's disease, potentially offering a new treatment target.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144664134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Network Meta-analysis of Capsule Endoscopy Versus Imaging Modalities for Diagnosing Small Bowel Crohn's Disease.","authors":"Shahryar Khan, Dushyant Singh Dahiya, Ahmed Khan Jadoon, Danish Ali Khan, Mashal Alam Khan, Falak Hamo, Hameed Ullah, Hareesha Rishab Bharadway, Yousaf Zafar, Sanket Basida, Shadi Hamdeh","doi":"10.1093/ecco-jcc/jjaf127","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf127","url":null,"abstract":"<p><strong>Introduction: </strong>Clinicians have several imaging options to evaluate suspected or confirmed small bowel Crohn's disease (SB-CD), including computed tomography enterography (CTE), magnetic resonance enterography (MRE), intestinal ultrasound (IUS), and video capsule endoscopy (VCE).</p><p><strong>Methods: </strong>Direct head-to-head comparative analysis and network meta-analysis were conducted on all available modalities using a random effects model. Furthermore, each modality was ranked using the surface under the cumulative ranking curve approach (P-score).</p><p><strong>Results: </strong>The present review included 29 studies with a total population of 2,609 individuals. The pooled sensitivity, specificity and diagnostic accuracy for the detection of SB-CD were 89.6%, 86.2% and 71.5% for VCE; 82%, 71.6% and 67.9% for MRE; 79.6%, 82.7% and 52.3% for CTE; and 89.3%, 72% and 71% for IUS, respectively. The network meta-analysis found that VCE exhibited superior diagnostic accuracy compared to CTE and MRE, while demonstrating comparable performance between VCE and IUS, as well as among MRE, CTE, and IUS. Further, the ranking analysis positioned VCE (P-score 0.97) as the most effective diagnostic modality for SB-CD, followed by IUS, MRE, and CTE. Subgroup analysis showed that VCE had significantly better diagnostic accuracy than the other modalities for detecting proximal SB-CD. Regarding adverse events, VCE was associated with capsule retention in 3.3% of the cases in these studies.</p><p><strong>Conclusions: </strong>VCE exhibited superior diagnostic performance for detecting established proximal SB-CD compared to other imaging modalities. Clinicians should weigh the benefits and risks, and incorporate other modalities, such as MRE and IUS to optimize diagnosis and management.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO Consensus on Dietary Management of Inflammatory Bowel Disease.","authors":"Vaios Svolos, Hannah Gordon, Miranda C E Lomer, Marina Aloi, Aaron Bancil, Alice S Day, Andrew S Day, Jessica A Fitzpatrick, Konstantinos Gerasimidis, Konstantinos Gkikas, Lihi Godny, Charlotte R H Hedin, Konstantinos Katsanos, Neeraj Narula, Richard K Russell, Chen Sarbagili-Shabat, Jonathan P Segal, Rotem Sigall-Boneh, Harry Sokol, Catherine L Wall, Kevin Whelan, Eytan Wine, Henit Yanai, Richard Hansen, Emma P Halmos","doi":"10.1093/ecco-jcc/jjaf122","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf122","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ECCO consensus on management of Inflammatory Bowel Disease in low-and middle-income countries.","authors":"Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena, Andy Darma, Karin Davidson, Nicolas Avellaneda, Muhammed Elhadi, April Roslani, Dakshitha Wickramasinghe, Carlo Angelo Cajucom, Shaji Sebastian","doi":"10.1093/ecco-jcc/jjaf125","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf125","url":null,"abstract":"<p><strong>Background: </strong>The incidence and prevalence of inflammatory bowel disease [IBD] have increased significantly in low- and middle-income countries [LMICs] in recent decades. Managing IBD in these settings presents substantial challenges. This consensus aims to describe the epidemiology of IBD in LMICs and to highlight the key challenges in its diagnosis and treatment.</p><p><strong>Method: </strong>The consensus-defining strategy followed the previous European Crohn's and Colitis Organisation [ECCO] consensus guidelines [available at www.ecco-ibd.eu]. The authors reviewed the available evidence and formulated statements accordingly. Provisional ECCO statements and supporting text were drafted based on a comprehensive literature review and further refined through two voting rounds, which included external reviewers and national representatives from ECCO's 36 member countries. The final ECCO statements, representing a consensus of at least 80% agreement among participants, were approved during an online meeting. Consensus statements should be interpreted in context with their accompanying commentary rather than in isolation and should not be used solely to guide patient management. The supporting text was finalized under the guidance of each working group leader [VP, HY, TK, AH] and subsequently integrated by the consensus leader [AE].</p><p><strong>Results: </strong>Data on IBD epidemiology in LMICs remain limited. Public and healthcare professional awareness and timely access to early diagnostic modalities, advanced medical and surgical therapies, and specialist multidisciplinary care are key gaps in IBD care in LMICs. The complexity and chronic nature of IBD, along with the necessity for a multidisciplinary approach, pose significant challenges to adopting a holistic management strategy in LMICs.</p><p><strong>Conclusion: </strong>There is a critical need for further studies to assess the specific needs of LMICs. Such research will help guide resource allocation and improve IBD management in these settings.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal hematopoiesis of indeterminate potential and risk of incident Crohn's disease-a prospective cohort study.","authors":"Yuqing Wang, Huiwen Xue, Ola Olén, Åsa H Everhov, Hui Wei, Qifa Liu, Qianwei Liu","doi":"10.1093/ecco-jcc/jjaf118","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf118","url":null,"abstract":"<p><strong>Background and aims: </strong>Crohn's disease (CD) is a chronic immune-mediated inflammatory disorder. Its pathophysiology involves dysregulation of both innate and adaptive immune responses, which can occur in clonal hematopoiesis of indeterminate potential (CHIP) individuals. Therefore, we hypothesize that CHIP may influence CD incidence. However, no study has explored the association between CHIP and incident CD. We analyzed UK Biobank data to investigate the association between CHIP and incident CD.</p><p><strong>Methods: </strong>CHIP was defined based on the whole-exome sequencing data. The outcome was incident CD. Cox regression models were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for CD in relation to CHIP.</p><p><strong>Results: </strong>This study included 461,913 participants, of whom 14,339 (3.1%) had CHIP. The incidence rate of CD was 21.6 and 37.7 per 100,000 person-years for individuals without and with CHIP, respectively. We found a statistically significant increased risk of CD among individuals with CHIP (HR: 1.68; 95% CI: 1.30-2.16), compared with the reference group. This association was particularly stronger in individuals with JAK2-mutant CHIP (HR: 7.28; 95% CI: 1.82-29.13), ASXL1-mutant CHIP (HR: 3.07; 95% CI: 1.74-5.44) and DNMT3A-mutant CHIP (HR: 1.73; 95% CI: 1.24-2.42). Additionally, the association did not vary greatly by demographic, socioeconomic, lifestyle factors, CHIP clone size, or cancer comorbidity.</p><p><strong>Conclusions: </strong>CHIP was associated with a markedly increased risk of subsequent CD. The association was particularly stronger in JAK2-mutant CHIP, ASXL1-mutant CHIP, and DNMT3A-mutant CHIP. The findings of this study may offer potential insights for future investigations into the mechanistic underpinnings of CD.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.","authors":"Jean-Frederic Colombel, Jianmin Wu, Taku Kobayashi, Baojin Zhu, Jerome Paulissen, Agni Dhanabal, Vipul Jairath, Corey Siegel, Britta Siegmund, Isabel Redondo, Richard Moses, Fernando Magro","doi":"10.1093/ecco-jcc/jjaf124","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf124","url":null,"abstract":"<p><strong>Background and aims: </strong>Concurrent achievement of symptomatic, endoscopic, and histologic remission, known as disease clearance, has been proposed as a treatment target in ulcerative colitis. Mirikizumab, an anti-interleukin-23 p19 antibody, has demonstrated long-term efficacy and safety, as reported in the LUCENT Phase 3 trials (NCT03518086, NCT03524092, and NCT03519945). The current analysis evaluates the impact of mirikizumab on disease clearance and the association with other clinical and patient-reported outcomes (PROs).</p><p><strong>Methods: </strong>LUCENT methods have previously been reported. The proportion of patients achieving disease clearance was determined through week (W)104. Association analyses were assessed between disease clearance and PROs (IBDQ, SF-36, WPAI:UC, PGRS, and PGRC), and early disease clearance and subsequent clinical outcomes (clinical, corticosteroid-free, endoscopic, histological, histologic-endoscopic, bowel urgency, stool frequency, and rectal bleeding).</p><p><strong>Results: </strong>The proportions of patients achieving disease clearance with mirikizumab at W12, W52, and W104 were 16.0%, 36.4%, and 51.3%, respectively. Mirikizumab-treated patients with disease clearance showed greater PRO improvements through W52 than those without. Early clearance at W12 was associated with significantly better clinical outcomes at later time points, except for bowel urgency remission at W52. This trend was repeated for clinical outcomes at W104 in patients who achieved disease clearance at W52.</p><p><strong>Conclusions: </strong>Mirikizumab consistently demonstrated disease clearance across induction, maintenance, and long-term studies. The attainment of disease clearance was associated with greater improvement in PROs, and early achievement of disease clearance was associated with better long-term outcomes, including clinical remission, corticosteroid-free remission, endoscopic and histological outcomes, reduced stool frequency, and rectal bleeding.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: A systematic review.","authors":"Hadar Meringer, Maia Kayal, Vipul Jairath, Anila Qasim, John K MacDonald, Yuhong Yuan, Christopher Ma, Jean-Frederic Colombel","doi":"10.1093/ecco-jcc/jjaf126","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf126","url":null,"abstract":"<p><strong>Background and aims: </strong>Endoscopy is important for assessing disease severity and potentially predicting treatment response in acute severe ulcerative colitis (ASUC). We aimed to identify and determine the operating properties of existing endoscopic indices/items used to assess disease activity in ASUC.</p><p><strong>Methods: </strong>MEDLINE, Embase, and Cochrane CENTRAL were searched from database inception to 17 April 2024 to identify individual items and scoring indices used to evaluate endoscopic disease activity in patients with ASUC. Subsequently, we performed another comprehensive search from database inception to 29 July 2024 to identify studies that assessed the validity, reliability, feasibility and responsiveness of the identified items and scoring indices.</p><p><strong>Results: </strong>We identified 18 studies that reported endoscopic measures in patients with ASUC, including Endoscopic Activity Index, Mayo endoscopic subscore (MES), Severe Endoscopic Lesions, Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score or sub-components of these indices. A total of 33 studies evaluated the operating properties of the MES, UCEIS, and DUBLIN score in ASUC. The MES and the UCEIS demonstrated adequate discriminant construct validity, convergent construct validity, and responsiveness. Feasibility or reliability were not assessed for these scores. The DUBLIN score demonstrated indeterminate discriminant construct validity and convergent construct validity with limited data. Responsiveness, feasibility, and reliability were not assessed for this score.</p><p><strong>Conclusions: </strong>These results highlight the need for a validated endoscopic score that can accurately describe and quantify the severity of endoscopic lesions and potentially predict outcomes in ASUC patients.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Risk of Mild, Moderate, and Severe Infections in IBD patients - A prospective, multicentre observational cohort study (PRIQ).","authors":"Ashkan Rezazadeh Ardabili, Dirk Van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Mariëlle Romberg-Camps, Marieke Pierik","doi":"10.1093/ecco-jcc/jjaf112","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf112","url":null,"abstract":"<p><strong>Background: </strong>In light of the growing number of treatment options, the benefit-risk balance of IBD drugs is increasingly important in clinical decision-making. Post-marketing surveillance studies are pivotal to assess infection risk, yet mainly focus on severe infections. This study aimed to assess the incidence and risk factors associated with mild, moderate, and severe infections in IBD patients.</p><p><strong>Methods: </strong>We previously developed and validated a Patient-Reported Infections Questionnaire (PRIQ) which accurately assesses 15 infection categories with a 3-month recall period. The current prospective, multicentre, observational cohort study was performed between June 1, 2020 and July 1, 2021, enrolling consecutive IBD patients using myIBDcoach. Incidence rates (IR) were calculated for all infections and negative binomial regression was utilized to identify risk factors for infections over time.</p><p><strong>Results: </strong>In total, 629 IBD patients (n=346 CD, n=283 UC, 58.3% female) were included, completing 2397 PRIQs during 573.8 person-years (PY) of follow-up. This resulted in 991 reported infections and an overall IR of 172.7 per 100PY, predominantly characterized by mild (IR 117.5 per 100PY) and moderate (IR 50.9 per 100PY) infections. Risk factors significantly associated with increased overall infection rates included female sex, higher comorbidity burden, smoking, and specific treatments, such as steroids, immunomodulators, anti-TNF agents, and JAK-inhibitors, with steroids doubling infection risk (IRR 2.02).</p><p><strong>Conclusion: </strong>Mild and moderate infections are common among IBD patients and are particularly associated with both patient characteristics and specific immunosuppressive treatments. These findings emphasize the need for vigilant monitoring, especially for patients at higher infection risk, and allow for more personalized advice on benefit-risk of IBD treatments.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adequacy of disclosures in oral presentations at the 20th Congress of European Crohn's and Colitis Organisation.","authors":"Ethan X Tan, Ziheng Calvin Xu, Robert D Little","doi":"10.1093/ecco-jcc/jjaf121","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf121","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}